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Background: Generalized anxiety disorder (GAD) is often presented with major depression 
(MD). GAD-MD can be a chronic and disabling condition, and patients suffering from this 
disorder often respond poorly to psychopharmacological treatment and experience side effects 
with medication. Therefore, there is a high demand for effective nonpharmacological therapy for 
GAD-MD patients. The current study explores the use of a radioelectric asymmetric conveyer 
(REAC) device in the treatment of GAD-MD.
Methods: Participants were 24 patients diagnosed with GAD-MD being treated at a public 
psychiatric center. All patients were dissatisfied with their current pharmacological treatment. 
Patients were evaluated using the 21-item Hamilton Depression (HAM-D) rating scale and 
the Symptom Check List-90-Revised (SCL-90R) before and after REAC brain stimulation 
treatment cycles.
Results: After REAC brain stimulation treatment, all patients experienced a significant reduction 
in anxiety and depression. These results were confirmed by physician examination, HAM-D 
scores, and SCL-90R total scores.
Conclusion: These results indicate a role for REAC brain stimulation in the management of 
  psychiatric conditions, specifically, GAD-MD comorbidity. REAC treatments are synergistic 
to drug therapy and appear to be helpful in reducing the side effects of medication. Future 
studies should evaluate the long-term effects of REAC treatment.
Keywords: anxiety disorders, depressive disorder, psychiatric somatic therapies, radioelectric 
asymmetric brain stimulation
Introduction
According to available epidemiological data, generalized anxiety disorder1–4 (GAD) 
is the most common anxiety disorder5–7 and one of the most common psychiatric 
conditions in the general population. The prevalence of GAD ranges from 4% to 
8%. However, the actual figure for this condition is most likely double that number. 
Although GAD can be a chronic and disabling condition with a poor response to 
  psychopharmacological treatment, it is one of the most unrecognized (both by the 
patient and the physician) and, consequently, undertreated mental pathologies.1,8,9 
Current therapies for GAD include serotonin and noradrenaline reuptake inhibitors10–12 
(eg, venlafaxine and duloxetine) and selective serotonin reuptake inhibitors12–18 
(eg, paroxetine and escitalopram), along with psychotherapeutic approaches,19,20 such 
as cognitive behavioral therapy.21–23 The delay in diagnosis, the chronic and continuous Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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nature of the disorder, and importantly, inadequate response 
to current drug therapies may lead to demoralization, which 
often complicates GAD with major depression (MD). Unlike 
other psychiatric disorders, to date there are no known 
“physical” treatment options (eg, transcranial magnetic 
stimulation) for patients suffering from GAD comorbid with 
MD. While the majority of patients suffering from GAD-MD 
are treated by private psychiatrists,24 the few who are seen 
in public psychiatric services are often seeking alternatives 
to traditional psychopharmacological treatment. The 
current study was conducted in a public psychiatry service 
outpatient setting with the goal of evaluating the efficacy 
of radioelectric asymmetric conveyer (REAC)25,26 brain 
stimulation in patients with comorbid GAD and MD. 
REAC treatments have proven efficacy in ameliorating 
motor behavior abnormalities,27 stress-related disorders, 
depression, anxiety,28–33 and bipolar disorder.34 In addition, 
REAC treatments are painless, noninvasive, and have no 
known adverse effects. The extensive use of “physical” 
approaches, such as REAC, as routine therapeutic protocols 
in the management of mental disorders, particularly those 
characterized by poor compliance and/or resistance to 
pharmacological treatment, is discussed.
Methods
The present study was approved by the Croce e Carle hospital 
ethics committee, Cuneo, Italy, and registered at the Australian 
New Zealand Clinical Trials Register. The study was con-
ducted according to the principles of the Declaration of 
Helsinki.
Twenty-four outpatients (20 females and four males, 
mean age 46.7 ± 8.9 years) diagnosed with GAD-MD 
using current Diagnostic and Statistical Manual of Mental 
Disorders Fourth Revision criteria and the Symptom 
Checklist-90-Revised (SCL-90R)35,36 participated in the 
study. The patients were being treated at the Psychiatric 
Hospital of Cuneo, Italy. All patients were dissatisfied 
with the results of their ongoing medical treatment of 
serotonin and noradrenaline reuptake inhibitors or selective 
serotonin reuptake inhibitors at a standard dose and duration 
of treatment. All participants were maintained on their 
current pharmacological treatment. At baseline (T0), the 
average 21-item Hamilton Depression (HAM-D)37 rating 
scale score was 15.5 ± 4.6, corresponding to a “mild” level 
of severity. The SCL-90R and HAM-D were administered 
prior to and after a standard cycle of REAC treatments (one 
Neuro Postural Optimization32 followed by 18 Neuro Psycho 
Physical Optimization32 sessions). Nine SCL-90R clusters 
were examined, ie, somatization, obsession-compulsion, 
interpersonal sensitivity, depression, anxiety, anger-
hostility, phobic anxiety, paranoid ideation, and psychotic 
behavior. The SCL-90R was specifically used due to its 
greater sensitivity to critical clinical aspects of anxiety (ie, 
interpersonal sensitivity and phobic anxiety) than the classic 
Hamilton Anxiety Scale (HAM-A).38 In addition, the overlap 
between HAM-D and HAM-A is well known.
REAC25,26 was applied using a medical device based on 
an innovative biostimulation technology. REAC typically 
runs within a frequency range of 2.4, 5.8, or 10.5 gHz. For 
the current study, a frequency of 10.5 gHz, with a specific 
absorption rate of 7 µW/kg, was used. The REAC pulse 
protocol was seven radiofrequency bursts of 500 msec each, 
applied by touching the metallic tip of the REAC probe 
(Convogliatore di Radianza Modulante, Asmed, Italy) to the 
ear pavilion using Neuro Postural Optimization and Neuro 
Psycho Physical Optimization protocols which have been 
described in detail elsewhere.31–34 The time interval from the 
initial clinical assessment until the last Neuro Psycho Physi-
cal Optimization session was approximately one month. Data 
were analyzed with t-tests, Wilcoxon signed-rank tests and 
Sign-tests. Statistical significance was set at P , 0.05.
Results
REAC treatments were well tolerated, with a good safety 
profile, and there were no withdrawals from the study due to 
side effects. After REAC treatment, all patients showed a sig-
nificant reduction in anxiety and depression   symptomatology. 
In addition, the clinical picture of each patient, as measured 
by physician evaluation, was described either as “improved” 
or “very improved.” Moreover, clinical improvement was 
confirmed by psychometric test scores (Figures 1–4 and 
Table 1). The average HAM-D total score decreased from 
15.5 ± 4.6 to 4.6 ± 2.2 (t = 10.472, df = 46, P , 0.001, see 
Figures 2 and 3). These results indicate an improvement from 
“mild depression” to an “absence of depression.” Scores on 
all clusters of the SCL-90R scale were significantly decreased 
after REAC treatment. Table 1 and Figure 4 show results for 
each specific symptomatic cluster on the SCL-90R scale, 
providing a more accurate picture of the quality of the clini-
cal response.
Discussion
REAC treatment resulted in significant decreases in both 
anxiety and depressive symptomatology. The remission of 
depressive symptomatology was demonstrated by a signifi-
cant decrease in average HAM-D total score. All patients, Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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after approximately 1 month of REAC treatment scored ,8 
on the HAM-D. In clinical terms, 1 month is similar to 
the delay of action of all categories of antidepressant and 
antianxiety medication.39 In addition, there was a notable 
response of all SCL-90R clusters to REAC treatment. The 
remission of psychiatric symptomatology was maximally 
affected27 in the majority of the clusters after Neuro   Psycho 
Physical Optimization treatment. Moreover, the effect was 
observed in clusters that are typically refractory to the 
action of psychotropic drugs (ie, interpersonal sensitivity, 
somatization, and psychotic behavior). These results may 
be related to complex cortical dysregulation40 which is not 
accessible to pharmacological action.
GAD-MD comorbidity often represents a psychopharma-
cological challenge, primarily due to a characteristic hyper-
sensitivity to side effects coupled with the need for a high 
drug dosage. GAD-MD seems particularly sensitive to Neuro 
Psycho Physical Optimization treatments using REAC.31–33 
In addition, REAC treatment appears to protect patients from 
jitteriness syndrome,41,42 which is frequently a cause of self-
withdrawal from medication in GAD-MD patients.
REAC treatment appears to work synergistically 
with classic drug treatment, thereby optimizing clinical 
results.34 Importantly, while all subjects continued medi-
cation during REAC treatment, many patients were able 
to reduce the dosage due to amelioration of their clinical 
  condition. These results are particularly beneficial in patients 
who experience side effects from their medication.34,30 
  Therefore, the reduction in drug dosage needed as a result 
of REAC treatment, significantly increased the safety and 
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Figure 2 hamilton Depression rating scale scores. sum of the values of each cluster, before and after Neuro Psycho Physical Optimization treatment.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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Figure 3 hamilton Depression rating scale scores, mean of the value for each cluster, before and after Neuro Psycho Physical Optimization treatment.
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Figure 4 Mean value of each symptom check List-90-revised cluster before and after Neuro Psycho Physical Optimization treatment.
tolerability profiles of serotonin and noradrenaline reuptake 
inhibitors and selective serotonin reuptake inhibitors.43–49
The mechanism of action of REAC treatment is mostly likely 
associated with remodulation of the abnormal brain activity seen 
in psychiatric disorders. This normalizing action appears to be 
crucial in anxiety disorders, where hyperfunctioning of newly 
developing, “reverberant,” and short intracortical   pathways is 
well established, and is most likely related to fear and avoidance 
behaviors.50–52 Recent magnetic resonance imaging studies have 
confirmed these hypotheses.34
Subjects in the current study showed a good response to 
REAC. The marked and rapid clinical efficacy, along with Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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safety, tolerability, and ease of use, suggests more extensive 
use of REAC in public as well as private psychiatric settings, 
and the possibility of use in additional psychiatric disorders. 
The beneficial effects of REAC treatment in bipolar disorder 
have recently been demonstrated.34
Amelioration of psychiatric symptoms using typical phar-
macological treatments is elusive, and therefore, an innova-
tive medical device such as REAC may serve as a beneficial 
adjunct. Moreover, REAC treatment sessions allow the physi-
cian to establish a close and more continuous relationship with 
patients. The doctor-patient relationship has been shown to be 
critical in promoting adherence to prescribed therapies.
While the current study was conducted exclusively in 
ambulatory patients, the advantages of REAC treatment 
may prove to be beneficial in the treatment of hospitalized 
patients. Further studies in a greater number of patients, using 
double-blind and placebo-controlled protocols, are needed. 
Long-term studies designed to evaluate the stability of REAC 
treatment are also required.
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